Abstract PS2-12-07: Metabolic and immune reprogramming via SCD1 inhibition enhances chemo-immunotherapy response in TNBC

Abstract Background: Triple-negative breast cancer (TNBC) is highly aggressive subtype with poor prognosis and there is an urgent need to develop novel therapies. Deregulated cellular energetics is a known hallmark of cancer. Stearoyl-CoA desaturase-1 (SCD1), is a key enzyme in fatty acid (FA) synthesis, converting saturated to monounsaturated FA. It is upregulated in TNBC, and its expression correlates with poor survival. Hence, targeting SCD1 is a novel strategy for cancer therapy. We have developed an SCD1 inhibitor, MTI-301 and shown anti-tumor activity in murine TNBC cell lines with MTI-301 alone and in combination with paclitaxel. Here, we study the efficacy of MTI-301 in TNBC mouse model and, molecular and immunological association of SCD1 in TNBC. Methods: MTI-301 activity (10 mg/kg oral gavage daily) was evaluated in E0771 immunocompetent TNBC mouse models alone and with immune checkpoint inhibitors (ICI) and paclitaxel (anti-PD-L1 Ab 200ug/mouse; IP and 25 mg/kg IP both given 2/week). Immune markers such as CD4+ T cell and CD8+ T cell in mice tumor tissue were assessed by immunohistochemistry (IHC). Tumor volume was measured by calipers 2/week and compared between groups by ANOVA test. Molecular and immune characterization was performed in 1,581 invasive ductal (ID) TNBC patient (pt) samples tested by NGS (592-gene panel, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences, Phoenix, AZ). ID-TNBC SCD1-high(H) and SCD1-low(L) RNA expression were classified as above or below the 50 percentiles, respectively. Immune cell fractions were calculated by deconvolution of WTS: Quantiseq. Pathway enrichment was determined by GSEA (Broad Inst). Statistical significance was determined using chi-square and Mann-Whitney U test with p-values adjusted for multiple comparisons (q0.05). Results: Compared to vehicle control, MTI-301 showed significant reduction in mean tumor volume and was associated with macrophage phagocytosis and intratumor infiltration of CD4 and CD8 T cells. We have also showed that MTI-301 + anti-PD1 Ab + paclitaxel has significant antitumor activity compared to either agent alone. IHC analysis is ongoing. In real-word pt data, SCD1-H TNBC (N=791) had higher immune cell infiltration of M2 MΦ (2.95% vs. 2.58%) and neutrophils (4.5% vs. 4.1%) compared to SCD1-L (N=790), all q0.05. SCD1-H had decreased IFNγ score (-0.29 vs -0.24), but increased MAPK activation score (-0.57 vs -1.77), all q0.05. SCD1-H had higher levels of metabolic regulator genes (IL10, IL10RA, SOCS3, HIF1A, DUSP6, FC: 1.4-1.8), immune checkpoint genes (PDCD1, CTLA4, LAG3, TIGIT, VISTA, CD244, CD160, BTLA, HAVCR2, FC: 1.3-1.6), stem cell related genes (CD44, ALDH1A1, ALDH1A2, ALDH1A3, KLF4, NANOG, FC: 1.4-1.6) and markers of exhausted T cells (CXCL13, CD38, CD101, ENTPD1, CD69, CD103, KLRG1, PRF1, GZMB, FC: 1.2-1.7), all q0.05. SCD1-H had enrichment of pathways related to oxidative phosphorylation, FA metabolism, PI3K/AKT/MTOR, EMT, DNA repair, TGF beta, P53 and inflammatory response (NES: 1.7-3.8, all FDR0.25). SCD1-H had higher frequency of PIK3CA (18.1% vs 8.8%), PTEN (10.7% vs 5.2%), PIK3R1 (6.4% vs 2.3%), AKT1 (3.3% vs 1.3%) and NF1 (8.3% vs 2.7%) mutation compared to SCD1-L, all q0.05. Conclusion: SCD1 high TNBC tumors are associated with immune suppressive TME, FA metabolism, and dysregulated PI3K pathway, positioning SCD1 as a metabolic driver of therapy resistance and immune evasion and support its targeting to enhance chemo-ICI efficacy. SCD1 inhibitor, MTI-301 significantly reduced tumor growth and enhanced effector immune cell infiltration in TNBC murine models with combinatorial activity with chemo-ICI, indicating that pharmacologic modulation of SCD1 is a promising strategy for cancer therapy. We will be conducting Phase I clinical trial with MTI-301 in pts with advanced tumors including TNBC (NCT NCT06911008). Citation Format: P. P. Advani, S. K. Deshmukh, R. Whetten, M. Redig, M. Pawlush, S. Wu, J. Xiu, J. P. Leone, S. Gandhi, M. Lustberg, G. Sledge Jr, J. Copland. Metabolic and immune reprogramming via SCD1 inhibition enhances chemo-immunotherapy response in TNBC abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-12-07.